This month’s Journal of Drugs in Dermatology issue brings forward a diverse collection of studies spanning surgical, medical, and therapeutic dermatology. The May Editor’s Pick presents a robust cost-effectiveness analysis on placental allograft use for same-day Mohs reconstruction, offering insights from more than 2,000 patients.
Also featured are a systematic review of cylindrocarcinoma surgical outcomes, a proposal for a universal classification of topical corticosteroids, and an expert consensus on hedgehog inhibitors in advanced BCC. Additional highlights include long-term data on triple-combo acne therapy, drug-induced keratoacanthomas, and cardiovascular safety of JAK inhibitors in AD.
Whether you’re focused on complex surgical cases, therapeutic innovations, or drug safety, the May issue offers data-driven guidance to enhance dermatologic care. Straight from the Editor’s desk, we share this month’s issue highlights:
Placental Allograft Reconstruction of Cutaneous Wounds Following Mohs Surgery: A Propensity Score-Matched Comparative Cost-Effectiveness Analysis discusses the results of 2,380 patients who underwent same-day reconstruction for high- and moderate-risk area defects.
Surgical Outcomes of Cylindrocarcinoma Treated With Mohs Micrographic Surgery and Excision: A Systematic Review utilizes PubMed and SCOPUS to identify articles addressing the treatment of cylindrocarcinoma through excision and/or MMS from inception to May 2024.
Topical Corticosteroid Potencies: Reimagining A New Universal Classification System aims to assess the factors that go into classifying TCS based on their potency and to propose a universal classification system.
Efficacy and Safety of Hedgehog Inhibitors for Advanced Basal Cell Carcinoma: An Expert Consensus Panel shares eight developed consensus statements related to the efficacy and safety of HHIs for laBCC.
Clinical Features and the Management of Drug-Induced Eruptive Keratoacanthoma and Squamous Cell Carcinoma: A Review of 172 Cases identifies significant differences in the clinical presentation of eruptive KA/SCC between drug etiologies.
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Results from a 6-Month Open-Label Study explores long-term efficacy, safety, and tolerability of CAB gel in participants with moderate or severe acne.
Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis evaluates the incidence of major adverse cardiovascular events (MACE) in patients with AD.
Successful Treatment of Sacral Pressure Injury With ACU-D1 presents the results of treating this common lesion that afflicts the elderly.
Find more JDD Issue Highlights here.
